PainReform Ltd.

NasdaqCM PRFX

PainReform Ltd. Net Cash Used For Investing Activities for the year ending December 31, 2023: USD 5.99 M

PainReform Ltd. Net Cash Used For Investing Activities is USD 5.99 M for the year ending December 31, 2023, a 199.75% change year over year. Net cash used for investing activities is total cash inflows and outflows related to activities intended to generate future income and cash flows from investments.

PainReform Ltd. Net Cash Used For Investing Activities for the year ending December 31, 2022 was USD -6.01 M, a -11,912.00% change year over year.
PainReform Ltd. Net Cash Used For Investing Activities for the year ending December 31, 2021 was USD -50.00 K, a -400.00% change year over year.
PainReform Ltd. Net Cash Used For Investing Activities for the year ending December 31, 2020 was USD -10.00 K, a 0.00% change year over year.
PainReform Ltd. Net Cash Used For Investing Activities for the year ending December 31, 2019 was USD 0.00.

Key data

Date	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure

NasdaqCM: PRFX

PainReform Ltd.

CEO	Dr. Ehud Geller Ph.D.
IPO Date	Sept. 1, 2020
Location	Israel
Headquarters	65 Yigal Alon Street
Employees	7
Sector	Health Care
Industries Pharmaceuticals Clinical Trials

Description

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.

Key trends

Past 5 years